Durable remissions with obinutuzumab-based chemoimmunotherapy: long-term follow-up of the phase 1b GALTON trial in CLL

Jennifer R. Brown, Susan O'Brien, C. Daniel Kingsley, Herbert Eradat, John M. Pagel, Jamie Hirata, Tammy McIver, Rodica Morariu-Zamfir and Thomas J. Kipps
PDF extract preview

This is a PDF-only article. The first page of the PDF of this article appears above.